Sunday, May 27, 2012

Powerful new approach to attack flu virus

ScienceDaily (May 27, 2012) ? An international research team has manufactured a new protein that can combat deadly flu epidemics.

The paper, featured on the cover of the current issue of Nature Biotechnology, demonstrates ways to use manufactured genes as antivirals, which disable key functions of the flu virus, said Tim Whitehead, assistant professor of chemical engineering and materials science at Michigan State University.

"Our most potent design has proven effective on the vulnerable sites on many pandemic influenza viruses, including several H1N1 (Spanish flu, Swine flu) and H5N1 (Avian flu) subtypes," said Whitehead, the paper's co-lead author. "These new therapeutics are urgently needed, so we were especially pleased to see that it neutralizes H1N1 viruses with potency."

From its earlier research, the team used computer-aided design to engineer proteins that targeted vulnerable sites on the highly adaptable virus. From there, researchers optimized their designer proteins by comprehensively mapping the mutations that gave the proteins a strong advantage when attacking the viruses' targeted areas.

The team improved its proteins through a process called "DNA deep sequencing." This allowed Whitehead and his colleagues to simultaneously sequence millions of variants of their manufactured proteins, identify and keep the beneficial mutations and optimize the proteins' performance.

"By taking only the best mutations, we can reprogram our proteins to burrow into viruses at key locations and render them harmless," he said. "Our work demonstrates a new approach to construct therapeutic proteins, which we hope will spur development of new protein drugs by the biopharmaceutical industry."

This research also laid the groundwork for future treatments of all flu viruses as well as other diseases such as smallpox, Whitehead added.

Whitehead's co-authors included researchers from the University of Washington, the Scripps Research Institute (La Jolla, Calif.), Naval Health Research Center (San Diego) and the Weizmann Institute of Science (Rehovot, Israel).

The research was funded by Defense Research Projects Agency, the Defense Threat Reduction Agency, the National Institutes of Health, the National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Michigan State University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Timothy A Whitehead, Aaron Chevalier, Yifan Song, Cyrille Dreyfus, Sarel J Fleishman, Cecilia De Mattos, Chris A Myers, Hetunandan Kamisetty, Patrick Blair, Ian A Wilson & David Baker. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nature Biotechnology, 27 May 2012 DOI: 10.1038/nbt.2214

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

pie crust recipe heritage foundation dancing with the stars results 2011 ali fedotowsky ali fedotowsky krill oil krill oil

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.